Britain's Competition Watchdog Probes Mega AstraZeneca Deal for US Biotech Firm

·1-min read

Britain’s competition watchdog on Tuesday said it was investigating the planned purchase of US biotech company Alexion by Covid vaccine-maker AstraZeneca in a deal worth $39 billion. In a brief statement, the Competition and Markets Authority said it was looking at whether the deal would “result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services”.

The planned tie-up, aimed at boosting AstraZeneca’s work on immunology, was announced in December as the London-listed company began to roll out the coronavirus vaccine it developed with the University of Oxford.

Read all the Latest News, Breaking News and Coronavirus News here

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting